November 6, 2017 05:17 PM ESTUpdated November 6, 09:17 PM

Japanese CMO Fujifilm Diosynth spends extra $28M in US, UK mAb facilities

Amber Tong

Fujifilm Diosynth Biotechnologies is channeling another $28 million from its parents company into two new manufacturing facilities in Texas and the UK, aggressively adding …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Japanese CMO Fujifilm Diosynth spends extra $28M in US, UK mAb facilities

Amber Tong

Sign up to read this article for free.

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Bristol Myers reveals more job cuts in New Jersey

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

AstraZeneca’s Truqap edges closer to prostate cancer label expansion with Phase 3 win

Japan­ese CMO Fu­ji­film Diosynth spends ex­tra $28M in US, UK mAb fa­cil­i­ties

Amber Tong

Sign up to read this article for free.

more like this

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

As­traZeneca’s Truqap edges clos­er to prostate can­cer la­bel ex­pan­sion with Phase 3 win

Japanese CMO Fujifilm Diosynth spends extra $28M in US, UK mAb facilities

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Bristol Myers reveals more job cuts in New Jersey

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

AstraZeneca’s Truqap edges closer to prostate cancer label expansion with Phase 3 win